Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Cash Flow: 2021-2024

Historic Net Cash Flow for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$91.6 million.

  • Amylyx Pharmaceuticals' Net Cash Flow rose 6325.65% to $166.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.4 million, marking a year-over-year increase of 341.90%. This contributed to the annual value of -$91.6 million for FY2024, which is 185.24% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Net Cash Flow stood at -$91.6 million, which was down 185.24% from $107.5 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Net Cash Flow registered a high of $107.5 million during FY2023, and its lowest value of -$91.6 million during FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Net Cash Flow value was $12.9 million (recorded in 2022), while the average stood at $9.6 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Net Cash Flow skyrocketed by 731.52% in 2023 and then tumbled by 185.24% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Net Cash Flow (Yearly) stood at $37.3 million in 2021, then plummeted by 65.34% to $12.9 million in 2022, then soared by 731.52% to $107.5 million in 2023, then plummeted by 185.24% to -$91.6 million in 2024.